

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 November 2002 (21.11.2002)

PCT

(10) International Publication Number
WO 02/092655 A1

(51) International Patent Classification⁷: C08G 4/00, A61L 27/00

(21) International Application Number: PCT/US02/14964

(22) International Filing Date: 10 May 2002 (10.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/854,435 11 May 2001 (11.05.2001) US

(71) Applicant: A.P. PHARMA, INC. [US/US]; 123 Saginaw Drive, Redwood City, CA 94063 (US).

(72) Inventors: NG, Steven, Y.; 1664 18th Avenue, San Francisco, CA 94122 (US). HELLER, Jorge; 45 Skywood Way, Woodside, CA 94062 (US).

(74) Agents: CHOW, Y., Ping et al.; Heller Ehrman White & McAuliffe LLP, 275 Middlefield Road, Menlo Park, CA 94025-3506 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/092655 A1

(54) Title: BIOERODIBLE POLY(ORTHOESTERS) CONTAINING HYDROGEN BONDING GROUPS

(57) Abstract: Bioerodible poly(orthoesters) useful as orthopedic implants or vehicles for the sustained delivery of pharmaceutical, cosmetic and agricultural agents contain hydrogen bonding groups and α -hydroxy acid-containing groups.

**BIOERODIBLE POLY(ORTHOESTERS)
CONTAINING HYDROGEN BONDING GROUPS**

BACKGROUND OF THE INVENTION

Field of the Invention

5 This application relates to poly(orthoesters). In particular, this invention relates to bioerodible poly(orthoesters) containing hydrogen bonding groups and α -hydroxy acid-containing groups.

Description of the Prior Art

10 Interest in synthetic biodegradable polymers for the systemic delivery of therapeutic agents began in the early 1970's with the work of Yolles *et al.*, *Polymer News* 1:9-15 (1970) using poly(lactic acid). Since that time, numerous other polymers have been prepared and investigated as bioerodible matrices for the controlled release of therapeutic agents.

15 U.S. Patent Nos. 4,079,038, 4,093,709, 4,131,648, 4,138,344 and 4,180,646 disclose biodegradable or bioerodible poly(orthoesters). These polymers are formed by a reaction between an orthoester (or orthocarbonate) such as 2,2-diethoxytetrahydrofuran and a diol such as 1,4-cyclohexanedimethanol. The reaction requires elevated temperature and reduced pressure and a relatively long reaction time. Drugs or other active agents are retained in the polymer matrix to be released as the polymer
20 biodegrades due to hydrolysis of the labile linkages.

 U.S. Patent No. 4,304,767 discloses polymers prepared by reacting a polyol with a polyfunctional ketene acetal. These polymers represent a significant improvement over those of U.S. Patent Nos. 4,079,038, 4,093,709, 4,131,648, 4,138,344 and 4,180,646, since synthesis proceeds readily at room temperature and atmospheric
25 pressure, and the resulting polymers have superior properties.

 Further polymers are disclosed in U.S. Patent No. 4,957,998. These polymers contain acetal, carboxy-acetal and carboxy-ortho ester linkages, and are prepared by a two-step process beginning with the reaction between a polyfunctional ketene acetal and a compound containing a vinyl ether, followed by reaction with a polyol or polyacid.

Still further polymers of a similar type are disclosed in U.S. Patent No. 4,946,931. The polymers are formed by a reaction between a compound containing a multiplicity of carboxylate functions and a polyfunctional ketene acetal. The resulting polymers have very rapid erosion times.

5 Despite the ease with which the orthoester linkage hydrolyses, poly(orthoesters) known in the prior art are extremely stable materials when placed in an aqueous buffer, or when residing in the body. This stability is attributable to the extreme hydrophobicity of the poly(orthoesters) which severely limits the amount of water that can penetrate the polymer. To achieve useful erosion rates, therefore, acidic excipients must be physically
10 incorporated into the polymer. While this allows control over erosion rates, the physically incorporated acidic excipient can diffuse from the polymer matrix at varying rates, leaving a matrix that is completely depleted of excipient while the polymer still has a very long lifetime remaining.


US Patent No. 5,968,543 (Heller et al.) describes poly(orthoesters) containing
15 α -hydroxy acid-containing groups. The poly(orthoesters) are formed from the reaction of a diketene acetal such as 3,9-di(ethylidene)-2,4,8,10-tetraoxaspiro[5.5]undecane (DETOSU) with at least 0.1 mol% of an " α -hydroxy acid" diol and 0 - 99.9 mol% of one or more of a "hard" diol and a "soft" diol (as those terms are used in the patent). These poly(orthoesters) are stated to have greater bioerodibility than similar poly(orthoesters)
20 not containing the α -hydroxy acid ester-containing groups, and to have the bioerodibility controllable by variation in the concentration of the α -hydroxy acid ester-containing groups.

U.S. Patent No. 4,549,010 (Sparer et al.) describes poly(orthoesters) containing functional groups which produce hydrogen bonding.

25 The disclosures of the documents listed in this section and elsewhere throughout this application are incorporated herein by reference.


SUMMARY OF THE INVENTION

In a first aspect, this invention is poly(orthoesters) of formula I:




where:

- 5 R^* is a C_{1-4} alkyl;
 n is an integer of at least 5; and
 each A is R^1 , R^2 , R^3 , or R^4 , where
 R^1 is:



- 10 where:


p is an integer of 1 to 20;
 R^5 is hydrogen or C_{1-4} alkyl; and
 R^6 is:




- 15 where:

s is an integer of 0 to 30;
 t is an integer of 2 to 200; and
 R^7 is hydrogen or C_{1-4} alkyl;

R² is:



R³ is:



5 where:

x is an integer of 0 to 30;

y is an integer of 2 to 200;

R⁸ is hydrogen or C₁₋₄ alkyl;

R⁹ and R¹⁰ are independently C₁₋₁₂ alkylene;

10 R¹¹ is hydrogen or C₁₋₆ alkyl and R¹² is C₁₋₆ alkyl; or R¹¹ and R¹² together are C₃₋₁₀ alkylene; and

R⁴ is a diol containing at least one functional group independently selected from amide, imide, urea, and urethane groups;

in which at least 0.1 mol% of the A units are R¹, and at least 0.1 mol% of the A units are

15 R⁴.

In a second aspect, this invention is controlled release pharmaceutical compositions comprising:

- (a) an active agent; and
- (b) as a vehicle, the poly(orthoester) described above.

20 In a third aspect, this invention is a method of treating a disease state treatable by controlled release local administration of an active agent, in particular treating pain by administration of a local anesthetic or treating cancer by administration of a chemotherapeutic or antineoplastic agent, comprising locally administering a therapeutically effective amount of the active agent in the form of the pharmaceutical composition described above.

25

In a fourth aspect, this invention is methods of using the poly(orthoesters) of the first aspect of the invention as bioerodible implants.

In a fifth aspect, this invention is methods of preparation of the poly(orthoesters) of the first aspect of the invention and the controlled release pharmaceutical
5 compositions of the second aspect of the invention.

DETAILED DESCRIPTION OF THE INVENTION

It has now been discovered that poly(orthoesters) useful as orthopedic implants or vehicles for the sequestration and sustained delivery of drugs, cosmetic agents and other beneficial agents can be prepared in such a manner that the rate and degree to
10 which they are hydrolyzed by contact with bodily fluids at normal body temperature and pH can be controlled without addition of exogenous acid. This discovery resides in the incorporation of esters of short-chain α -hydroxy acids such as esters of glycolic acid, lactic acid or glycolic-co-lactic acid copolymer into the poly(orthoester) chain and variation of the amount of these esters relative to the poly(orthoester) as a whole.

15 In the presence of water, these esters, when incorporated into the poly(orthoester) chain, are readily hydrolyzed at a body temperature of 37°C and a physiological pH, in particular at a pH of 7.4, to produce the corresponding α -hydroxy acids. The α -hydroxy acids then act as an acidic excipient to control the hydrolysis rate of the poly(orthoester). When the poly(orthoester) is used as a vehicle or matrix entrapping an active agent, the
20 hydrolysis of the poly(orthoester) causes release of the active agent.

In addition, the mechano-physical state of the poly(orthoester) may also be controlled. This is achieved by the inclusion of the residues of certain diols in selected proportions relative to the poly(orthoester) as a whole. For example, a high content of the residue of *1,4-cyclohexanedimethanol* or a similar "hard" diol relative to a "soft"
25 diol (definition of which is given below) produces a relatively rigid polymer chain and a more solid substance, and by decreasing the 1,4-cyclohexanedimethanol content relative to the "soft" diol, the poly(orthoester) will change progressively through the stages of a rigid thermoplastic, a soft thermoplastic, a low melting solid to an ointment-like (viscous liquid) material, and any stage in between.

30 The poly(orthoesters) of the present invention are prepared by condensation reactions between diketene acetals and polyols, preferably diols, and the variation in

mechano-physical state and rate of hydrolysis (bioerodibility) is achieved by the selection and use of combinations of different types of diols and diketene acetals.

Definitions

"Active agent" includes any compound or mixture of compounds which produces a beneficial or useful result. Active agents are distinguishable from such components as vehicles, carriers, diluents, lubricants, binders and other formulating aids, and encapsulating or otherwise protective components. Examples of active agents are pharmaceutical, agricultural or cosmetic agents. Suitable pharmaceutical agents include locally or systemically acting pharmaceutically active agents which may be administered to a subject by topical or intralesional application (including, for example, applying to abraded skin, lacerations, puncture wounds, etc., as well as into surgical incisions) or by injection, such as subcutaneous, intradermal, intramuscular, intraocular, or intra-articular injection. Examples of these agents include, but not limited to, anti-infectives (including antibiotics, antivirals, fungicides, scabicides or pediculicides), antiseptics (e.g., benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, mafenide acetate, methylbenzethonium chloride, nitrofurazone, nitromersol and the like), steroids (e.g., estrogens, progestins, androgens, adrenocorticoids, and the like), therapeutic polypeptides (e.g., insulin, erythropoietin, morphogenic proteins such as bone morphogenic protein, and the like), analgesics and anti-inflammatory agents (e.g., aspirin, ibuprofen, naproxen, ketorolac, COX-1 inhibitors, COX-2 inhibitors, and the like), cancer chemotherapeutic agents (e.g., mechlorethamine, cyclophosphamide, fluorouracil, thioguanine, carmustine, lomustine, melphalan, chlorambucil, streptozocin, methotrexate, vincristine, bleomycin, vinblastine, vindesine, dactinomycin, daunorubicin, doxorubicin, tamoxifen, and the like), narcotics (e.g., morphine, meperidine, codeine, and the like), local anesthetics (e.g., the amide- or anilide-type local anesthetics such as bupivacaine, dibucaine, mepivacaine, procaine, lidocaine, tetracaine, and the like), antiangiogenic agents (e.g., combrestatin, contortrostatin, anti-VEGF, and the like), polysaccharides, vaccines, antigens, DNA and other polynucleotides, antisense oligonucleotides, and the like. The present invention may also be applied to other locally acting active agents, such as astringents, antiperspirants, irritants, rubefacients, vesicants, sclerosing agents, caustics, escharotics, keratolytic

agents, sunscreens and a variety of dermatologics including hypopigmenting and antipruritic agents. The term "active agents" further includes biocides such as fungicides, pesticides, and herbicides, plant growth promoters or inhibitors, preservatives, disinfectants, air purifiers and nutrients.

5 "Alkyl" denotes a linear saturated hydrocarbyl having from one to the number of carbon atoms designated, or a branched or cyclic saturated hydrocarbyl having from three to the number of carbon atoms designated (e.g., C₁₋₄ alkyl). Examples of alkyl include methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, t-butyl, cyclopropylmethyl, and the like.

10 "Alkylene" denotes a branched or unbranched saturated divalent radical having from one to the number of carbon atoms designated (e.g., C₁-C₁₂ alkylene). Examples of alkylene include methylene (-CH₂-), ethylene (-CH₂CH₂-), isopentylene (-CH₂-CH(CH₃)-CH₂-CH₂-), n-octylene (-CH₂)₈- and the like.

15 "Bioerodible" and "bioerodibility" refer to the degradation, disassembly or digestion of the poly(orthoester) by action of a biological environment, including the action of living organisms and most notably at physiological pH and temperature. A principal mechanism for bioerosion of the poly(orthoesters) of the present invention is hydrolysis of linkages between and within the units of the poly(orthoester).

20 "Comprising" is an inclusive term interpreted to mean containing, embracing, covering or including the elements listed following the term, but not excluding other unrecited elements.

25 "Controlled release", "sustained release", and similar terms are used to denote a mode of active agent delivery that occurs when the active agent is released from the delivery vehicle at an ascertainable and controllable rate over a period of time, rather than dispersed immediately upon application or injection. Controlled or sustained release may extend for hours, days or months, and may vary as a function of numerous factors. For the pharmaceutical composition of the present invention, the rate of release will depend on the type of the excipient selected and the concentration of the excipient in the composition. Another determinant of the rate of release is the rate of hydrolysis of the linkages between and within the units of the poly(orthoester). The rate of hydrolysis
30 in turn may be controlled by the composition of the poly(orthoester) and the number of hydrolyzable bonds in the poly(orthoester). Other factors determining the rate of release

of an active agent from the present pharmaceutical composition include particle size, acidity of the medium (either internal or external to the matrix) and physical and chemical properties of the active agent in the matrix.

“Matrix” denotes the physical structure of the poly(orthoester) which essentially
5 retains the active agent in a manner preventing release of the agent until the poly(orthoester) erodes or decomposes.

“Sequestration” is the confinement or retention of an active agent within the internal spaces of a poly(orthoester) matrix. Sequestration of an active agent within the matrix may limit the toxic effect of the agent, prolong the time of action of the agent in a
10 controlled manner, permit the release of the agent in a precisely defined location in an organism, or protect unstable agents against the action of the environment.

A “therapeutically effective amount” means the amount that, when administered to an animal for treating a disease, is sufficient to effect treatment for that disease.

“Treating” or “treatment” of a disease includes preventing the disease from
15 occurring in an animal that may be predisposed to the disease but does not yet experience or exhibit symptoms of the disease (prophylactic treatment), inhibiting the disease (slowing or arresting its development), providing relief from the symptoms or side-effects of the disease (including palliative treatment), and relieving the disease (causing regression of the disease). For the purposes of this invention, a “disease”
20 includes pain.

A “unit” denotes an individual segment of a poly(orthoester) chain, which consists of the residue of a diketene acetal molecule and the residue of a polyol.


An “ α -hydroxy acid containing” unit denotes a unit where A is R^1 , i.e. in which the polyol is prepared from an α -hydroxy acid or cyclic diester thereof and a diol of the
25 formula $HO-R^6-OH$. The fraction of the poly(orthoester) that is α -hydroxy acid containing units affects the rate of hydrolysis (or bioerodibility) of the poly(orthoester), and in turn, the release rate of the active agent.

“Hard”, “soft”, and “hydrogen bonding” units denote individual units of the poly(orthoester), the contents of which relative to the poly(orthoester) as a whole
30 determine the mechano-physical state of the poly(orthoester). “Hard” units are units where A is R^2 , “soft” units are units where A is R^3 , and “hydrogen bonding” units are units where A is R^4 .

“Vehicle” and “carrier” denote an ingredient that is included in a composition such as a pharmaceutical or cosmetic preparation for reasons other than a therapeutic or other biological effect. Functions served by vehicles and carriers include transporting an active agent to a site of interest, controlling the rate of access to, or release of, the active agent by sequestration or other means, and facilitating the application of the agent to the region where its activity is needed.

The poly(orthoesters)

The poly(orthoesters) are of formula I




10 where:

R* is a C₁₋₄ alkyl;

n is an integer of at least 5; and

each A is R¹, R², R³, or R⁴, where

R¹ is:




15

where:

p is an integer of 1 to 20;

R⁵ is hydrogen or C₁₋₄ alkyl; and

R⁶ is:



5


where:

s is an integer of 0 to 30;


t is an integer of 2 to 200; and

R⁷ is hydrogen or C₁₋₄ alkyl;

10 R² is:



R³ is:



where:

15 x is an integer of 0 to 30;

y is an integer of 2 to 200;

R⁸ is hydrogen or C₁₋₄ alkyl;

R⁹ and R¹⁰ are independently C₁₋₁₂ alkylene;

- R^{11} is hydrogen or C_{1-6} alkyl and R^{12} is C_{1-6} alkyl; or R^{11} and R^{12} together are C_{3-10} alkylene; and
- R^4 is a diol containing at least one functional group independently selected from amide, imide, urea, and urethane groups;
- 5 in which at least 0.1 mol% of the A units are R^1 , and at least 0.1 mol% of the A units are R^4 .

Because these poly(orthoesters) are polymers, the number of repeating units necessarily represents an average value of a distribution rather than an exact number. Similarly, the number of α -hydroxy acid groups p in the α -hydroxy acid containing

10 units, and the number of ethylene oxide groups s and x in the R^6 and R^3 groups, respectively, also necessarily represent average values of a distribution rather than an exact number.

The structure of the poly(orthoester) useful for the present invention, as shown in formula I, is one of alternating residues of a diketene acetal and a diol, with each

15 adjacent pair of diketene acetal residues being separated by the residue of one polyol, preferably a diol.

In the presence of water, the α -hydroxy acid containing units are readily hydrolyzed at a body temperature of 37°C and a physiological pH, to produce the corresponding hydroxy acids. These hydroxy acids then act as acidic catalysts to control

20 the hydrolysis rate of the poly(orthoester) without the addition of exogenous acid. When the poly(orthoester) is used as a delivery vehicle or matrix entrapping an active agent, the hydrolysis of the poly(orthoester) causes release of the active agent.

Poly(orthoesters) having a higher mole percentage of the " α -hydroxy acid containing" units will have a higher rate of bioerodibility. Preferred poly(orthoesters)


25 are those in which the mole percentage of the " α -hydroxy acid containing" units is in the range of 1 to 50 mole percent, more preferably from 2 to 30 mole percent, for example from 5 to 30 mole percent, especially from 10 to 30 mole percent.

Preferred poly(orthoesters) are those where:

n is an integer of 5 to 1000, preferably 20 to 500, especially 30 to 300;


R⁵ is hydrogen or methyl;

R⁶ is:



where s is an integer of 0 to 10, especially 1 to 4; t is an integer of 2 to 30, especially 2 to 10; and R⁷ is hydrogen or methyl;

R³ is:



R⁴ is selected from aliphatic diols of 2 to 20 carbon atoms, preferably 2 to 10 carbon atoms, interrupted by one amide, imide, urea, or urethane group; and

the proportion of units in which A is R¹ is 1 - 50 mol%, preferably 2 - 30 mol%,
15 more preferably 5 - 30 mol%.

While the presence of any of these preferences results in a poly(orthoester) that is more preferred than the same poly(orthoester) in which the preference is not met, the preferences are generally independent, and poly(orthoesters) in which a greater number of preferences is met will generally result in a poly(orthoester) that is more preferred
20 than that in which a lesser number of preferences is met.

Expressed in terms of mole percent of the "hard" or "hydrogen bonding" unit relative to the poly(orthoester) as a whole, preferred poly(orthoesters) for liquid or ointment-like compositions are those in which the "hard" or "hydrogen bonding" unit constitutes 20 mole percent or less. Likewise, preferred poly(orthoesters) for more solid
25 compositions are those in which the "hard" or "hydrogen bonding" unit constitutes from 60 mole percent to 99.9 mole percent.

Poly(orthoesters) having a higher content of the "α-hydroxy acid containing" unit will have a higher rate of bioerodibility. Preferred poly(orthoesters) are those in which

the "α-hydroxy acid containing" units constitute preferably from 1 to 50 mole percent, more preferably from 2 to 30 mole percent, for example from 5 to 30 mole percent, especially from 10 to 30 mole percent.


With respect to the individual "α-hydroxy acid containing" unit, p is preferably 1 to 6, more preferably 1 to 4, most preferably 1 or 2; R⁵ is preferably hydrogen or methyl; and in the above definitions of R⁶, s is preferably 2 to 12, more preferably 2 to 6 and most preferably 2; and t is preferably 4 to 12, more preferably 4 to 6 and most preferably 6.

With respect to the individual "hard" unit, R² is preferably 1,4-cyclohexane-dimethanol.

With respect to the individual "soft" unit, in the definitions of R³, x is preferably 2 to 12, more preferably 2 to 6 and most preferably 2; y is preferably 4 to 12, more preferably 4 to 6 and most preferably 6; R⁸ is preferably hydrogen; R⁹ and R¹⁰ are preferably identical, more preferably an unbranched C₄-C₁₂ alkylene and most preferably an unbranched C₆-C₁₂ alkylene; R¹¹ is preferably hydrogen and R¹² is preferably methyl.

Preparation of the Poly(orthoesters)

The poly(orthoesters) are prepared according to the methods described in US Patents Nos. 4,549,010 and 5,968,543. Specifically, the poly(orthoesters) are prepared by the reaction of a diketene acetal of formula II:



where L is hydrogen or a C₁₋₃ alkyl,

with a diol of the formula HO-R¹-OH and a diol of the formula HO-R⁴-OH, and optionally at least one diol of the formulae HO-R²-OH and HO-R³-OH.

The rigidity or flexibility of the poly(orthoester) is determined by the proportions of the "hard" and "hydrogen bonding" units and "soft" units in the poly(orthoester) structure, with greater rigidity achieved by including greater proportions of the "hard" and "hydrogen bonding" units in the poly(orthoester).

The bioerodibility of the poly(orthoester) is determined by the proportion of the hydrolyzable α -hydroxy acid ester groups, with greater bioerodibility achieved by including greater proportions of the " α -hydroxy acid containing" units.

Thus, both characteristics of the resulting poly(orthoester) prepared from the
5 reaction between the diketene acetal of formula II and a mixture of the diols, are controlled by the ratio of quantities of the two to four types of diols in the diol mixture.

It is also understood that the present invention encompasses cross-linked poly(orthoesters) which are prepared by employing one or more polyols having more than two hydroxy functional groups. Such cross-linked poly(orthoesters) may be
10 prepared preferably by first reacting the diketene acetal with a mixture of diols comprising a diol of the formula $\text{HO-R}^1\text{-OH}$ and a diol of the formula $\text{HO-R}^4\text{-OH}$, and optionally at least one diol of the formula $\text{HO-R}^2\text{-OH}$ and $\text{HO-R}^3\text{-OH}$, followed by addition of the polyol(s) having more than two hydroxy functional groups. Alternatively, the polyol(s) having more than two hydroxy functional groups may be
15 added simultaneously with the diols of formulae $\text{HO-R}^1\text{-OH}$ and $\text{HO-R}^4\text{-OH}$ and other diols. Polyols having more than two hydroxy functional groups suitable for the preparation of the cross-linked poly(orthoesters) may be the straight or branched chain type, including polyhydroxyl compounds such as 1,2,3-propanetriol, 1,2,5-pentanetriol, 1,2,6-hexanetriol, 1,3,5-pentanetriol, 1,2,4-butanetriol, 1,4,7-heptanetriol, 1,5,10-
20 decanetriol, 1,5,12-dodecanetriol, 1,2,3,4,5,6-hexane-hexol and the like. Other representative polyols of the type are described in US Patent No. 4,304,767. The reaction conditions (*e.g.*, suitable solvents and reaction temperatures) and procedures for the preparation of the cross-linked poly(orthoesters) are similar to those described above for the preparation of the poly(orthoesters) employing only the diols, and are also
25 described in US Patents Nos. 4,304,767 and 5,968,543.


The preparation of the diketene acetals of formula II is disclosed in U.S. Patent Nos. 4,304,767, 4,532,335, and 5,968,543; and will be known to a person of ordinary skill in the art. A typical method is the condensation of pentaerythritol with two equivalents of a 2-halocarboxaldehyde dialkyl acetal, such as 2-bromoacetaldehyde
30 diethyl acetal, followed by dehydrohalogenation to give the diketene acetal. The condensation of a glycol with diethylbromoacetals is described in Roberts et al., *J. Am.*

Chem. Soc., 80, 1247-1254 (1958), and dehydrohalogenation is described in Beyerstedt et al., *J. Am. Chem. Soc.*, 58, 529-553 (1936).

The diketene acetals may also be prepared by the isomerization of divinyl acetals. Thus, for example, 3,9-di(ethylidene)-2,4,8,10-tetraoxaspiro[5.5]undecane
5 (DETOSU) may be prepared by the isomerization of 3,9-divinyl-2,4,8,10-tetraoxaspiro[5.5]undecane, using *n*-butyllithium in ethylenediamine. The isomerization of the double bond is described in Corey et al., *J. Org. Chem.*, 38, 3224 (1973). The divinyl acetals may be prepared by the condensation of a bis(diols) such as pentaerythritol with two equivalents of a vinylic aldehyde, such as acrolein or
10 crotonaldehyde, or their dialkyl acetals, such as acrolein dimethyl acetal, and such condensation reactions are well known.

The diols of the formulae HO-R¹-OH, HO-R²-OH, HO-R³-OH, and HO-R⁴-OH are prepared according to methods known in the art, and as described, for example, in U.S. Patents Nos. 4,549,010 and 5,968,543. Some of the diols are commercially
15 available. The diol of the formula HO-R¹-OH that comprises a polyester moiety may be prepared by reacting a diol of the formula HO-R⁶-OH with between 0.5 and 10 molar equivalents of a cyclic diester of an α -hydroxy acid, such as lactide or glycolide, and allowing the reaction to proceed at 100 - 200 °C for about 12 hours to about 48 hours. Although particular solvents are not required for this reaction, organic solvents such as
20 dimethylacetamide, dimethyl sulfoxide, dimethylformamide, acetonitrile, pyrrolidone, tetrahydrofuran, and methylbutyl ether may be used. Diols of the formula HO-R⁴-OH include diols where R⁴ is R'CONR''R' (amide), R'CONR''COR' (imide), RNR''CONR''R' (urea), and R'OCONR''R' (urethane), where each R' is independently an aliphatic, aromatic, or aromatic/aliphatic straight or branched chain hydrocarbyl,
25 especially a straight or branched chain alkyl of 2 to 22 carbon atoms, especially 2 to 10 carbon atoms, and more especially 2 to 5 carbon atoms, and R'' is hydrogen or C₁₋₆ alkyl, especially hydrogen or methyl, more especially hydrogen. Some representative diols of the formula HO-R⁴-OH include *N,N'*-bis-(2-hydroxyethyl)terephthalamide, *N,N'*-bis-(2-hydroxyethyl)pyromellitic diimide, 1,1'-methylenedi(p-phenylene)-
30 bis-[3-(2-hydroxyethyl)urea], *N,N'*-bis-(2-hydroxyethyl)oxamide, 1,3-bis(2-hydroxyethyl)urea, 3-hydroxy-*N*-(2-hydroxyethyl)propionamide, 4-hydroxy-*N*-(3-hydroxypropyl)butyramide, and bis(2-hydroxyethyl)ethylenedicarbamate. These

diols are known to the art in reported syntheses and many are commercially available. Representative diols of the formula $\text{HO}-(\text{CH}_2)_n-\text{NHCO}-(\text{CH}_2)_m-\text{OH}$ where n is an integer of 2 to 6 and m is an integer of 2 to 5 are made by the reaction of 2-aminoethanol, 3-aminopropanol, 4-aminobutanol, 5-aminopentanol, or 6-aminohexanol with β -propiolactone, γ -butyrolactone, δ -valerolactone, or ϵ -caprolactone. Representative diols of the formula $\text{HO}-(\text{CH}_2)_n-\text{NHCOO}-(\text{CH}_2)_m-\text{OH}$ where n and m are each integers of 2 to 6 are made by the reaction of the same aminoalcohols just mentioned with cyclic carbonates of the formula



such as ethylene carbonate. Bis-amide diols of the formula $\text{HO-A-NHCO-B-CONH-A-OH}$ are prepared by the reaction of a diacid, optionally in activated form, such as the diacyldihalide, with two equivalents of a hydroxy-amine. Other methods of preparation of the diols of the formula $\text{HO-R}^4-\text{OH}$ are known in the art.

Once made, the diol of the formula $\text{HO-R}^1-\text{OH}$ and the diol of the formula $\text{HO-R}^4-\text{OH}$, and the diol(s) of the formulae $\text{HO-R}^2-\text{OH}$ and $\text{HO-R}^3-\text{OH}$ in the desired proportions are mixed with the diketene acetal of formula II, in a slightly less than 1:1 (e.g., 0.5:1 - 0.9:1) ratio of total number of moles of diketene acetal to total number of moles of diols, in a suitable solvent at ambient temperature. The condensation reaction between the diketene acetal and the diols is carried out under conditions which are described in, for example, U.S. Patent Nos. 4,304,767, 4,549,010, and 5,968,543, and are well known to those skilled in the art; and will also be readily apparent from the structures of the reactants themselves. Suitable solvents are aprotic solvents, such as dimethylacetamide, dimethyl sulfoxide, dimethylformamide, acetonitrile, acetone, ethyl acetate, pyrrolidone, tetrahydrofuran, and methylbutyl ether, and the like. Catalysts are not required for this reaction, but when used, suitable catalysts are iodine in pyridine, *p*-toluenesulfonic acid; salicylic acid, Lewis acids (such as boron trichloride, boron trifluoride, boron trichloride etherate, boron trifluoride etherate, stannic oxychloride, phosphorous oxychloride, zinc chloride, phosphorus pentachloride, antimony pentafluoride, stannous octoate, stannic chloride, diethyl zinc, and mixtures thereof); and Brønsted catalysts (such as polyphosphoric acid, crosslinked polystyrene sulfonic

acid, acidic silica gel, and mixtures thereof). A typical amount of catalyst used is about 0.2% by weight relative to the diketene acetal. Smaller or larger amounts can also be used, such as 0.005% to about 2.0% by weight relative to the diketene acetal. Once the reaction is complete, the reaction mixture is allowed to cool and concentrated by
5 rotoevaporation under vacuum. The concentrated mixture may be further dried under vacuum at an elevated temperature.

The poly(orthoesters) may also be prepared by reaction of the diketene acetal with the chosen diol(s) under similar reaction conditions, but in the presence of a "chain stopper" (a reagent that terminates poly(orthoester) chain formation). Suitable chain
10 stoppers are C₅₋₂₀ alkanols, especially C₁₀₋₂₀ alkanols. The chain stopper is preferably present in from 1 - 20 mol% based on the diketene acetal. The poly(orthoesters) thus prepared have lower molecular weights with a lower molecular weight dispersion than those prepared by the reaction of the diketene acetals with only diols.

It is also understood that the present invention encompasses cross-linked
15 polymers which are prepared by employing one or more polyols having more than two hydroxy functional groups. Such cross-linked polymers may be prepared preferably by first reacting the diketene acetal with a mixture of diols comprising a diol of the formula HO-R¹-OH and a diol of the formula HO-R⁴-OH, and optionally diol(s) of the formulae HO-R²-OH and HO-R³-OH followed by addition of the polyol(s) having more than two
20 hydroxy functional groups. Alternatively, the polyol(s) having more than two hydroxy functional groups may be added simultaneously with the of the formula HO-R¹-OH and the diol of the formula HO-R⁴-OH and other diols. Polyols having more than two hydroxy functional groups suitable for the preparation of the cross-linked polymers may be the straight or branched chain type, including polyhydroxyl compounds such as 1,2,3-
25 propanetriol, 1,2,5-pentanetriol, 1,2,6-hexanetriol, 1,3,5-pentanetriol, 1,2,4-butanetriol, 1,4,7-heptanetriol, 1,5,10-decanetriol, 1,5,12-dodecanetriol, 1,2,3,4,5,6-hexane-hexol and the like. Other representative polyols of the type are described in U.S. Patent No. 4,304,767. The reaction conditions (e.g., suitable solvents and reaction
temperatures) and procedures for the preparation of the cross-linked polymers are
30 similar to those described above for the preparation of the polymers employing only the diols, and are also described in US Patent No. 4,304,767.

The invention includes poly(orthoesters) which contain all four types of units as well as poly(orthoesters) containing from only the " α -hydroxy acid containing" units and "hydrogen bonding" units, or a mixture of these units with only one of the "hard" units or "soft" units. It also includes poly(orthoesters) prepared from a mixture of units which
5 contains two or more diols of the same type.

Uses of the Poly(orthoesters)

The present poly(orthoesters) can be used for any use in which bioerodible polymers are usable, such as vehicles for the sustained release of an active agent or as orthopedic implants.

10 To use the poly(orthoester) as a sustained-release vehicle, the active agent must be incorporated into a matrix of the poly(orthoester) or encapsulated within a capsule (or a "microcapsule" or "nanocapsule", as those terms are sometimes used) of the poly(orthoester). Methods for the preparation of sustained-release dosage forms using biodegradable polymers are well known in the art, as discussed in the references cited in
15 the "Description of the Prior Art" section of this application, and in other references familiar to those of ordinary skill in the art; so that a person of ordinary skill in the art would have no difficulty, having regard to that skill and this disclosure, in preparing sustained-release formulations using the poly(orthoester) of this invention. Suitable active agents include therapeutic agents such as pharmaceutical or pharmacological
20 active agents, *e.g.*, drugs and medicaments, as well as prophylactic agents, diagnostic agents, and other chemicals or materials useful in preventing or treating disease. The compositions of this invention are particularly useful for the therapeutic treatment of humans and other mammals, but may also be used for other animals. In addition, the sustained-release compositions of this invention may also be used for the release of
25 cosmetic and agricultural agents, or for the release of biocides, such as fungicides or other pesticides, into an environment where prolonged release of the active agent is desired.

In the case of matrix formulations, the poly(orthoester) is first mixed with the active agent. High homogeneity may be achieved by mixing the poly(orthoester) in its
30 heat softened state with the active agent, followed by lowering the temperature to harden the composition. Alternatively, the poly(orthoester) can be dissolved in an appropriate

casting solvent, such as tetrahydrofuran, methylene chloride, chloroform or ethyl acetate, and the active agent can then be dispersed or dissolved in the poly(orthoester) solution, followed by evaporating the solvent to achieve the finished composition. Another method is grinding a solid poly(orthoester) material into powder which is then mixed
5 with a powdered active agent. The active agent may also be incorporated into the mixture of monomers before polymerization provided that it is stable under the polymerization conditions and does not interfere with the polymerization reaction.

If the active agent is one that is unstable at elevated temperatures (*e.g.*, above 40°C), or in the presence of organic solvents or organic solvent/water mixtures, such as a
10 protein, then special preparation techniques may be required to minimize the exposure of the active agent to damaging conditions. Such techniques are disclosed in, for example, U.S. Patents Nos. 5,620,697 (Törmälä et al., assigned to Orion-Yhtymä Oy and Leiras Oy), which discloses ultrasonic melting to form matrix-type pharmaceutical compositions, and 5,518,730 (Fuisz, assigned to Fuisz Technologies, Inc.), which
15 discloses melt-spinning, both of which techniques are designed to minimize the exposure of the polymer and active to elevated temperatures. Other methods are disclosed in the patents and literature references cited elsewhere in this application.

An alternate method for the incorporation and release of sensitive therapeutic agents is to use bioerodible poly(orthoesters) that have physical properties tailored for
20 this incorporation. For example, the poly(orthoester) may be chosen so that it is semi-solid and has an ointment-like consistency, rather than being fully solid. Thus, a poly(orthoester) may be chosen that has a very high viscosity at normal body temperature of 37 °C so that little if any deformation takes place at that temperature. However, the viscosity of the poly(orthoester) may decrease substantially at
25 temperatures no higher than 45 °C, or preferably by 40 °C, so that injection of the material may be possible at a temperature at which the active agent retains its activity.

The composition obtained from any of the above methods can be readily processed into a variety of shapes and forms for implantation, insertion or placement on the body or into body cavities or passageways. For example, the poly(orthoester)
30 composition may be injection molded, extruded or compressed into a thin film or made into devices of various geometric shapes or forms such as flat, square, round, cylindrical, tubular, disc, ring and the like. Rod- or pellet-shaped devices may be

implanted through a trocar, such as is known for Norplant® implants, and these or other shapes may be implanted by minor surgical procedures. Alternatively, a device may be implanted following a major surgical procedure such as tumor removal in the surgical treatment of cancer.

5 The poly(orthoester) composition may also be injected by syringe subcutaneously or intramuscularly as particles of 0.1µm to 1000µm, preferably 0.5µm to 200µm, and more preferably 1µm to 150µm suspended in a pharmaceutically acceptable injection base. Liquid vehicles useful for suspending the drug-poly(orthoester) composition for injection include isotonic saline solution or oils (such as corn oil,

10 cottonseed oil, peanut oil and sesame oil) which, if desired, may contain other adjuvants.

Another injectable dosage form may be prepared from an active agent mixed in with a poly(orthoester) of the present invention which has an ointment-like consistency. Such a dosage form may be administered by injection with or without a solvent.

15 The poly(orthoester) composition administered by either injection or implantation undergoes bioerosion in the body into non-toxic and non-reactive materials. By controlling the number of hydrolyzable bonds in the poly(orthoester), the active agent may be released at a desired rate. Implants prepared from the present poly(orthoesters) in which the poly(orthoester) constitutes the matrix containing an active agent also have the advantage that they do not require removal because of the

20 bioerodibility of the poly(orthoester).

In some cases, particles with cores of the pure active agent coated with various thicknesses of the present poly(orthoester) may be preferred for sustained delivery of the active agent. Coating or encapsulation of discrete particles of the active agent may be accomplished by conventional methods which are all well-known to the person skilled

25 in the art. For example, finely divided drug particles may be suspended in a solvent system (in which the drug is not soluble) containing the dissolved poly(orthoester) and other excipients, followed by spray drying. Alternatively, the drug particles may be placed in a rotating pan or a fluid-bed dryer and the poly(orthoester) dissolved in a carrier solvent is sprayed onto the drug particles until a suitable coating quantity is

30 deposited on the particles to give a desired thickness. The coating may also be achieved by suspending the drug particles in a solvent system containing the dissolved

poly(orthoester) followed by adding to the suspension a non-solvent causing the poly(orthoester) to precipitate and form a coating over the drug particles.

For the sustained release compositions, because the active agent will be released over a controlled period of time, the agent usually is present in an amount which is
5 greater than the conventional single dose. The relative proportions of the active agent and the poly(orthoester) can vary over a wide range (*e.g.*, 0.1 to 50 weight percent) depending on the therapeutic agent and the desired effect.

Sustained compositions of cosmetic and agricultural agents may also be prepared by any one of the methods as described above, using the poly(orthoesters) of the present
10 invention.

The solid poly(orthoesters) (those containing a high percentage of the "hard" unit and/or a high proportion of the "hydrogen bonding" unit) are also useful for a variety of orthopedic applications. For example, they can be used as fracture fixation devices for repair of osteochondral defects, ligament and tendon reconstructions and bone
15 substitutes. In addition, the fact that the present poly(orthoesters) permit simultaneous selection of both a desired level of their mechano-physical state and a desired rate of bioerodibility, also renders them attractive as grafts or scaffolds on which cells can be cultured *in vitro* prior to implantation to regenerate tissues. Tissues which can be regenerated using this approach include but not limited to, bone, tendon, cartilage,
20 ligaments, liver, intestine, ureter and skin tissues. For example, the poly(orthoesters) may be used to regenerate skin for patients with burns or skin ulcers. Cartilages may be repaired by first isolating chondrocytes from a patient (or a donor), allowing them to proliferate on the scaffolds prepared from the present poly(orthoester) and re-implanting the cells in the patient.

25 The poly(orthoester) scaffolds or implants may further contain other biologically active substances or synthetic inorganic materials such as reinforcing filler material for enhancing the mechanical properties of the scaffolds or implants (*e.g.*, calcium sodium metaphosphate fibers), antibiotics or bone growth factors to induce and/or promote orthopedic restoration and tissue regeneration.

30 The compositions are also stable. The release rates of the active agent are not affected by irradiation for sterilization.

Particular Compositions and their Uses

Exemplary compositions of this invention, and their uses, include:

- (1) compositions containing local anesthetics, optionally in combination with glucocorticosteroids such as dexamethasone, cortisone, hydrocortisone, prednisone, prednisolone, beclomethasone, betamethasone, flunisolide, fluocinolone acetonide, fluocinonide, triamcinolone, and the like, for the prolonged relief of local pain or a prolonged nerve blockade. This use is discussed further below;
- (2) compositions containing cancer chemotherapeutic agents, such as those listed above under "Active Agents", for deposition by syringe or by injection into tumors or operative sites from which a tumor has been ablated, for tumor control or treatment and/or the suppression of regrowth of the tumor from residual tumor cells after ablation of the tumor;
- (3) compositions containing progestogens, such as flurogestone, medroxyprogesterone, norgestrel, norgestimate, norethindrone, and the like, for estrus synchronization or contraception;
- (4) compositions containing antimetabolites such as fluorouracil and the like, as an adjunct to glaucoma filtering surgery; compositions containing antiangiogenic agents such as combrestatin, for the treatment of macular degeneration and retinal angiogenesis; and other compositions for the controlled release of ophthalmic drugs to the eye;
- (5) compositions containing therapeutic polypeptides (proteins), such as insulin, LHRH antagonists, and the like, for the controlled delivery of these polypeptides, avoiding the need for daily or other frequent injection;
- (6) compositions containing anti-inflammatory agents such as the NSAIDs, e.g. ibuprofen, naproxen, COX-1 or COX-2 inhibitors, and the like, or glucocorticosteroids, for intra-articular injection;
- (7) compositions containing antibiotics, for the prevention or treatment of infection, especially for deposition into surgical sites to suppress post-operative infection, or into or on wounds, for the suppression of infection (e.g. from foreign bodies in the wound);
- (8) compositions containing morphogenic proteins such as bone morphogenic protein; and

- (9) compositions containing DNA or other polynucleotides, such as antisense oligonucleotides.

Delivery of Controlled-release Local Anesthetics by Injection

Local anesthetics induce a temporary nerve conduction block and provide pain relief which lasts from a few minutes to a few hours. They are frequently used to prevent pain in surgical procedures, dental manipulations or injuries.

The synthetic local anesthetics may be divided into two groups: the slightly soluble compounds and the soluble compounds. Conventionally, the soluble local anesthetics can be applied topically and by injection, and the slightly soluble local anesthetics are used only for surface application. The local anesthetics conventionally administered by injection can also be divided into two groups, esters and non-esters. The esters include (1) benzoic acid esters (piperocaine, mepylcaine and isobucaine); (2) *para*-aminobenzoic acid esters (procaine, tetracaine, butethamine, propoxycaine, chloroprocaine); (3) *meta*-aminobenzoic acid esters (metabutethamine, primacaine); and (4) *para*-ethoxybenzoic acid ester (parethoxycaine). The non-esters are anilides (amides or nonesters) which include bupivacaine, lidocaine, mepivacaine, pytrocaine and prilocaine.

Many of the local anesthetics are conventionally used in the form of their acid addition salts, as this provides solubility in aqueous injection media. However, because the presence of the large amount of acid within such a local anesthetic acid addition salt will result in more rapid degradation of the poly(orthoesters) and release of the local anesthetic, it is generally desirable to use the local anesthetics in free base form, or with only a small proportion of the acid addition salt present (addition of small quantities of the acid addition salt may provide enhanced release if desired).

The semi-solid injectable form of a local anesthetic of the present invention is prepared by incorporating the local anesthetic into the delivery vehicle in a manner as described above. The concentration of the local anesthetic may vary from 1 - 60 wt.%, preferably 5 - 30 wt.%, e.g. about 10 wt.%. The semi-solid composition is then filled into a syringe with a 18-25 gauge needle, and injected into sites that are painful or to be subjected to surgical procedures. The semi-solid injectable composition of the present

invention can be used for controlled delivery of both slightly soluble and soluble local anesthetics.


Because the duration of action of a local anesthetic is proportional to the time during which it is in actual contact with nervous tissues, the present injectable delivery system can maintain localization of the anesthetic at the nerve for an extended period of time which will greatly prolong the effect of the anesthetic.

A number of authors, including Berde et al., U.S. Patent No. 6,046,187 and related patents, have suggested that the co-administration of a glucocorticosteroid may prolong or otherwise enhance the effect of local anesthetics, especially controlled-release local anesthetics; and formulations containing a local anesthetic and a glucocorticosteroid, and their uses for controlled release local anesthesia, are within the scope of this invention.

EXAMPLE

The following synthesis illustrates the preparation of a poly(orthoester) of this invention.

The poly(orthoester) in this example is prepared from DETOSU, a diol of formula III:



trans-1,4-cyclohexanedimethanol (*t*-CDM), and 4-hydroxy-*N*-(3-hydroxypropyl)-butyramide. The molar ratio of the four components (DETOSU:diol of formula III:*t*-CDM:4-hydroxy-*N*-(3-hydroxypropyl)butyramide) is 100:9:90:1.


Under rigorously anhydrous conditions, DETOSU (40 mmol), diol of formula III (3.6 mmol), *t*-CDM (36 mmol), and 4-hydroxy-*N*-(3-hydroxypropyl)butyramide (0.4 mmol) are weighed into a 250 mL round bottom flask, and the mixture dissolved in anhydrous tetrahydrofuran (75 mL). To this solution is added a *p*-toluenesulfonic acid solution in tetrahydrofuran (5 drops, 40 mg/mL) to initiate the polymerization. The solution comes to a boil within a few minutes. The solution is allowed to cool to room temperature, then is slowly poured with vigorous stirring into an excess of methanol

(800 mL) containing triethylamine (1 mL) as a stabilizer. The precipitated poly(orthoester) is collected and dried overnight in a vacuum oven at 40°C.

The foregoing is offered primarily for purposes of illustration. It will be readily apparent to those skilled in the art that the molecular structures, proportions of the
5 reactant materials, methods of use and other parameters of the invention described herein may be further modified or substituted in various ways without departing from the spirit and scope of the invention.


WHAT IS CLAIMED IS:

1. A poly(orthoester) of formula I:




where:


- 5 R* is a C₁₋₄ alkyl;
 n is an integer of at least 5; and
 each A is R¹, R², R³, or R⁴, where
 R¹ is:




- 10 where:
 p is an integer of 1 to 20;
 R⁵ is hydrogen or C₁₋₄ alkyl; and
 R⁶ is:



- 15 where:
 s is an integer of 0 to 30;
 t is an integer of 2 to 200; and
 R⁷ is hydrogen or C₁₋₄ alkyl;
 R² is:




R^3 is:




where:

- 5 x is an integer of 0 to 30;
 y is an integer of 2 to 200;
 R^8 is hydrogen or C_{1-4} alkyl;
 R^9 and R^{10} are independently C_{1-12} alkylene;
 R^{11} is hydrogen or C_{1-6} alkyl and R^{12} is C_{1-6} alkyl; or R^{11} and R^{12} together are C_{3-10} alkylene; and
- 10 R^4 is a diol containing at least one functional group independently selected from amide, imide, urea, and urethane groups;
 in which at least 0.1 mol% of the A units are R^1 , and at least 0.1 mol% of the A units are R^4 .
- 15 2. The poly(orthoester) of Claim 1 where n is 5 to 1000.
3. The poly(orthoester) of Claim 2 where n is 20 to 500.
4. The poly(orthoester) of Claim 3 where n is 30 to 300.
5. The poly(orthoester) of Claim 1 which comprises 1 to 50 mole percent of units in which A is $-O-R^1-$.
- 20 6. The poly(orthoester) of Claim 5 which comprises 2 to 30 mole percent of units in which A is R^1 .

7. The poly(orthoester) of Claim 6 which comprises 5 to 30 mole percent of units in which A is R¹.
8. The poly(orthoester) of Claim 7 which comprises 10 to 30 mole percent of units in which A is R¹.
- 5 9. The poly(orthoester) of Claim 1 where p is 1 to 6.
10. The poly(orthoester) of Claim 9 where p is 1 to 4.
11. The poly(orthoester) of Claim 10 where p is 1 to 2.
12. The poly(orthoester) of Claim 1 where R⁵ is hydrogen or methyl.
13. The poly(orthoester) of Claim 1 which comprises up to 20 mole percent of units in which A is R² or R⁴.
- 10 14. The poly(orthoester) of Claim 1 which comprises 60 to 99.9 mole percent of units in which A is R² or R⁴.
15. A process of preparing a poly(orthoester) of formula I:




- 15 where:
- R* is a C₁₋₄ alkyl;
- n is an integer of at least 5; and
- each A is R¹, R², R³, or R⁴, where
- R¹ is:



- 20 where:
- p is an integer of 1 to 20;

R^5 is hydrogen or C_{1-4} alkyl; and

R^6 is:




where:

5 s is an integer of 0 to 30;


t is an integer of 2 to 200; and

R^7 is hydrogen or C_{1-4} alkyl;

R^2 is:



10 R^3 is:



where:

x is an integer of 0 to 30;

y is an integer of 2 to 200;

15 R^8 is hydrogen or C_{1-4} alkyl;


R^9 and R^{10} are independently C_{1-12} alkylene;

R^{11} is hydrogen or C_{1-6} alkyl and R^{12} is C_{1-6} alkyl; or R^{11} and R^{12} together are C_{3-10} alkylene; and

R^4 is a diol containing at least one functional group independently selected from amide, imide, urea, and urethane groups;

in which at least 0.1 mol% of the A units are R^1 , and at least 0.1 mol% of the A units are R^4 ,

- 5 the process comprising reacting a diketene acetal of formula II:




where L is hydrogen or a C_{1-3} alkyl,

with a diol of the formula $HO-R^1-OH$ and a diol of the formula $HO-R^4-OH$, and optionally at least one diol of the formulae $HO-R^2-OH$ and $HO-R^3-OH$.


- 10 16. A poly(orthoester) that is the product of a reaction between:

(a) a diketene acetal of formula II:



where L is hydrogen or a C_{1-3} alkyl, and

- (b) a polyol or mixture of polyols in which at least 0.1 mole percent of the
15 total polyol content is a diol of the formula $HO-R^1-OH$, where
 R^1 is:




where:

p is an integer of 1 to 20;

- 20 R^5 is hydrogen or C_{1-4} alkyl; and

R^6 is:



where:

s is an integer of 0 to 30;

t is an integer of 2 to 200; and

5 R^7 is hydrogen or C_{1-4} alkyl; and

at least 0.1 mole percent of the total polyol content is a diol of the formula $HO-R^4-OH$, where R^4 is the residue of a diol containing at least one functional group independently selected from amide, imide, urea, and urethane groups.

17. The poly(orthoester) of Claim 16 where at least one of the polyols is a polyol
10 having more than two hydroxy functional groups.

18. A device for orthopedic restoration or tissue regeneration comprising a poly(orthoester) of Claim 1.

19. A bioerodible implant comprising a poly(orthoester) of Claim 1.

20. A pharmaceutical composition comprising:
15 (a) an active agent; and
(b) as a vehicle, the poly(orthoester) of Claim 1.

21. The pharmaceutical composition of Claim 20 where the fraction of the active agent is from 1% to 60% by weight of the composition.

22. The pharmaceutical composition of Claim 21 where the fraction of the active
20 agent is from 5% to 30% by weight of the composition.

23. The pharmaceutical composition of Claim 20 where the active agent is selected from anti-infectives, antiseptics, steroids, therapeutic polypeptides, anti-inflammatory agents, cancer chemotherapeutic agents, narcotics, local anesthetics, antiangiogenic agents, vaccines, antigens, DNA, and antisense oligonucleotides.
- 5 24. The pharmaceutical composition of Claim 20 where the active agent is a therapeutic polypeptide.
25. The pharmaceutical composition of Claim 20 where the active agent is a local anesthetic.
26. The pharmaceutical composition of Claim 25 further comprising a
10 glucocorticosteroid.
27. The pharmaceutical composition of Claim 20 where the active agent is an antiangiogenic agent.
28. The pharmaceutical composition of Claim 20 where the active agent is a cancer chemotherapeutic agent.
- 15 29. The pharmaceutical composition of Claim 20 where the active agent is an antibiotic.
30. The pharmaceutical composition of Claim 20 where the active agent is an anti-inflammatory agent.
31. A method of treating a disease state treatable by controlled release local
20 administration of an active agent, comprising locally administering a therapeutically effective amount of the active agent in the form of a pharmaceutical composition of Claim 20.
32. The method of Claim 31 where the active agent is selected from anti-infectives, antiseptics, steroids, therapeutic polypeptides, anti-inflammatory agents, cancer
25 chemotherapeutic agents, narcotics, local anesthetics, antiangiogenic agents, vaccines, antigens, DNA, and antisense oligonucleotides.

33. A method of preventing or relieving local pain at a site in a mammal, comprising administering to the site a therapeutically effective amount of a local anesthetic in the form of a pharmaceutically acceptable composition of Claim 20.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/14964

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5968543	A	19-10-1999	AT 197310 T	15-11-2000
			AU 1527097 A	01-08-1997
			BR 9706960 A	28-12-1999
			CA 2242631 A1	17-07-1997
			DE 69703430 D1	07-12-2000
			DE 69703430 T2	03-05-2001
			EP 0869986 A1	14-10-1998
			ES 2153648 T3	01-03-2001
			JP 2000512322 T	19-09-2000
			PT 869986 T	30-04-2001
			WO 9725366 A1	17-07-1997
US 4549010	A	22-10-1985	NONE	
WO 0185139	A	15-11-2001	AU 6151601 A	20-11-2001
			WO 0185139 A2	15-11-2001